Shots: EU approval is based on results of APOLLO P-III study involving 19 countries in ratio (2:1) assessing Onpattro vs PBO once q3w for 18mos showing safety and efficacy Onpattro RNA interference (RNAi) will be launch in Germany for the treatment of Hereditary Transthyretin-Mediated (hATTR) with improved QoL Onpattro is an IV RNAi therapeutic developed […]Read More
